By
David Finegold, Strategy & Organization Studies, Keck Graduate Institute for the Applied Life Sciences
Cecile Bensimon, University of Toronto Joint Centre for Bioethics
Abdallah Daar, University of Toronto Joint Centre for Bioethics
Margaret Eaton, Stanford University Center for Biomedical Ethics
Beatrice Godard, Faculté de médecine, Université de Montréal
Bartha Knoppers, Faculté de droit, Université de Montréal
Jocelyn Mackie, University of Toronto Joint Centre for Bioethics
Peter Singer, University of Toronto Joint Centre for Bioethics
Description
This book is the first systematic, detailed treatment of the approaches to ethical issues taken by biotech and pharmaceutical companies.
The application of genetic/genomic technologies raises a whole spectrum of ethical questions affecting global health that must be addressed.
Topics covered in this comprehensive survey include considerations for bioprospecting in transgenics, genomics, drug discovery, and nutrigenomics,
as well as how to improve stakeholder relations, design ethical clinical trials, avoid conflicts of interest, and establish ethics advisory
boards. The expert authors represent multiple disciplines including law, medicine, bioinformatics, pharmaceutics, business, and ethics.
Audience:
Advanced undergraduate and graduate students in courses focusing on biotechnology in business, law medicine, biology and public health;
Managers and employees in biotech and pharmaceutical companies as well as venture capitalists and financial analysts
